Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.